1[1]Manoharan M. 2e - carbohydrate modifications in antisense oligonucleotide therapy: importance of conformation ,configuration and conjugation[J]. Biochim Biophys Acta, 1999,1489:117.
2[2]Gryaznov SM. Oligonucleotide N3eAP5' phosphoramidates as potential therapeutic agents[J]. Biochim Biophys Acta, 1999 1489: 131.
3[3]Wong DK, Cheung AM, O'Rourke K, etal. Effect of alpha- interferon treatment in patients with hepatitis B e antigen - positive chronic hepatitis B: a meta- analysis[J] .Ann Intern Med, 1993,119: 312.
4[4]Robaczewska M, G uerret S, Remy JS, et al. Inhibition of hepadnaviral replication by polyethylenimine - based intravenous delivery of antisense phosphodiester oligodeoxynucleotides to the liver[J]. Gene Ther, 2001,8: 874.
5[5]McHutchison JG. Hepatitis C advances in antiviral therapy:what is accepted treatment now?[J] .J Gastroenterol Hepatol, 2002,17: 431.
6[6]Manns MP, McHutchison JG, Gordon SC, et al. Pegintefferon alfa - 2b plus ribavirin compared with interferon alfa - 2b plus ribavirin for initial treatment of chronic hepatitis C:a rancdomised trial[J]. 1ancet, 2001,358: 958.
7[7]Di Bisceglie AM, McHutchison J, Rice CM. New therapeutic strategies for hepatitis C[J]. Hepatology, 2002, 35: 224.
8[8]Macejsk DG, Jensen KL, Jamison SF, et al. Inhibition of hepatitis C virus (HCV) - RNA - dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes [J]. Hepatology,2000,31:769.
9[9]Michel ML, Pol S, Brechot C,et al. Immunotherapy of chronic hepatitis B by anti HBV vaccine:from present to future[J] .Vaccine,2001,19:2395.
10[10]Loirat D,Lemonnier FA,Michel ML.Multiepitopic HLA-A* 0201-restricted immune response against hepatitis B surface antigen after DNA - based immunization [ J ]. J Immunol, 2000,165: 4748.
